ArticleJournal of cancer research and clinical oncology2026
Favorable pathological response with enfortumab vedotin plus toripalimab as neoadjuvant therapy for HER2-negative muscle-invasive bladder cancer: a case report.
Xi Zhang et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.